| Diffuse Large B-Cell Lymphoma
Columvi vs Monjuvi
Side-by-side clinical, coverage, and cost comparison for diffuse large b-cell lymphoma.Deep comparison between: Columvi vs Monjuvi with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsMonjuvi has a higher rate of injection site reactions vs Columvi based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Monjuvi but not Columvi, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Columvi
Monjuvi
At A Glance
IV infusion
Every 3 weeks
CD20xCD3 bispecific T-cell engager
IV infusion
Every 2 weeks
CD19-directed monoclonal antibody
Indications
- Diffuse Large B-Cell Lymphoma
- Diffuse Large B-Cell Lymphoma
Dosing
Diffuse Large B-Cell Lymphoma Pretreat with obinutuzumab 1,000 mg IV on Cycle 1 Day 1; then administer COLUMVI IV: 2.5 mg step-up dose on Cycle 1 Day 8, 10 mg step-up dose on Cycle 1 Day 15, then 30 mg on Day 1 of Cycles 2-12 (21-day cycles; maximum 12 cycles or until disease progression or unacceptable toxicity).
Diffuse Large B-Cell Lymphoma 12 mg/kg IV; Cycle 1: Days 1, 4, 8, 15, and 22; Cycles 2-3: Days 1, 8, 15, and 22; Cycle 4 and beyond: Days 1 and 15 of each 28-day cycle; in combination with lenalidomide for up to 12 cycles, then MONJUVI as monotherapy until disease progression or unacceptable toxicity.
Contraindications
—
—
Adverse Reactions
Most common (>=20%) Cytokine release syndrome, musculoskeletal pain, rash, fatigue
Serious Cytokine release syndrome, COVID-19 infection, sepsis, tumor flare
Most common (>=20%) Neutropenia, fatigue, anemia, diarrhea, thrombocytopenia, cough, pyrexia, peripheral edema, respiratory tract infection, decreased appetite
Serious Infections (including pneumonia, febrile neutropenia), cerebrovascular accident, respiratory failure, progressive multifocal leukoencephalopathy, sudden death
Pharmacology
Glofitamab-gxbm is a bispecific CD20-directed CD3 T-cell engager that binds CD20 on B cells and CD3 on T cells, causing T-cell activation and proliferation, cytokine secretion, and lysis of CD20-expressing B cells.
Tafasitamab-cxix is an Fc-modified CD19-directed monoclonal antibody that mediates B-cell lysis through apoptosis, antibody-dependent cellular cytotoxicity (ADCC), and antibody-dependent cellular phagocytosis (ADCP); in combination with lenalidomide, it demonstrates increased ADCC activity in DLBCL tumor cells.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Columvi
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (0/12) · Qty limit (0/12)
Monjuvi
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (0/12) · Qty limit (0/12)
UnitedHealthcare
Columvi
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Monjuvi
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Columvi
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (0/3)
Monjuvi
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
$0
Genentech Patient FoundationCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableCancerCare: Non-Hodgkin Lymphoma
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
ColumviView full Columvi profile
MonjuviView full Monjuvi profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.